Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

CHOP chemotherapy regimen PETAL Study NCT00554164 - CHOP chemotherapy regimen

- 20/9/21 - 1 formulario, 17 itemgroups, 83 items, 2 idiomas

Itemgroups: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, G-CSF, Cycle duration, Therapy discontinuation, Stem Cell Mobilization, Lab results prior to chemotherapy cycle, Lab results during interval after chemotherapy cycle, Toxicity, Intercurrent disease, Footer module

Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

(R)-ESHAP PETAL Study NCT00554164 - (R)-ESHAP

- 20/9/21 - 1 formulario, 17 itemgroups, 84 items, 2 idiomas

Itemgroups: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, G-CSF, Cycle duration, Therapy discontinuation, Stem Cell Mobilization, Lab results prior to chemotherapy cycle, Lab results during interval after chemotherapy cycle, Toxicity, Intercurrent disease, Footer module

Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

(R)-DHAP PETAL Study NCT00554164 - (R)-DHAP

- 20/9/21 - 1 formulario, 17 itemgroups, 83 items, 2 idiomas

Itemgroups: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, G-CSF, Cycle duration, Therapy discontinuation, Stem Cell Mobilization, Lab results prior to chemotherapy cycle, Lab results during interval after chemotherapy cycle, Toxicity, Intercurrent disease, Footer module

Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

Pre-phase Therapy PETAL Study NCT00554164 - Pre-phase Therapy

- 20/9/21 - 1 formulario, 10 itemgroups, 41 items, 2 idiomas

Itemgroups: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, Intercurrent disease, Footer module

Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

Visit 16 GIMEMA CML0408 NCT00769327 - Visit 16

- 20/9/21 - 1 formulario, 11 itemgroups, 117 items, 2 idiomas

Itemgroups: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, FISH (from bone marrow blood), Molecular Biology (peripheral blood), FISH (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 16 Form

Visit 13 GIMEMA CML0408 NCT00769327 - Visit 13

- 20/9/21 - 1 formulario, 5 itemgroups, 56 items, 2 idiomas

Itemgroups: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Molecular Biology (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 13 Form

Visit 5 GIMEMA CML0408 NCT00769327 - Visit 5

- 20/9/21 - 1 formulario, 4 itemgroups, 44 items, 2 idiomas

Itemgroups: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 5 Form

Visit 7 GIMEMA CML0408 NCT00769327 - Visit 7

- 20/9/21 - 1 formulario, 13 itemgroups, 127 items, 2 idiomas

Itemgroups: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, NILOTINIB, FISH (from bone marrow blood), IMATINIB, Molecular Biology (peripheral blood), FISH (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 7 Form